Share This Page
Drug Price Trends for NDC 58151-0125
✉ Email this page to a colleague
Average Pharmacy Cost for 58151-0125
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| EFFEXOR XR 37.5 MG CAPSULE | 58151-0125-77 | 16.86273 | EACH | 2025-11-19 |
| EFFEXOR XR 37.5 MG CAPSULE | 58151-0125-93 | 16.86273 | EACH | 2025-11-19 |
| EFFEXOR XR 37.5 MG CAPSULE | 58151-0125-77 | 16.86273 | EACH | 2025-10-22 |
| EFFEXOR XR 37.5 MG CAPSULE | 58151-0125-93 | 16.86273 | EACH | 2025-10-22 |
| EFFEXOR XR 37.5 MG CAPSULE | 58151-0125-77 | 16.86126 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 58151-0125
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 58151-0125
Introduction
The drug identified by the National Drug Code (NDC) 58151-0125 is a pharmaceutical product registered with the FDA, serving a specific therapeutic area. Given the dynamic landscape of pharmaceutical markets—marked by evolving patent statuses, regulatory changes, and competitive forces—comprehensive analysis of its market positioning and pricing trends is essential for stakeholders. This report provides an in-depth examination of the current market landscape, competitive environment, demand drivers, regulatory influences, and future price projections for NDC 58151-0125.
Product Overview
While specific details about NDC 58151-0125 require access to proprietary databases such as First Databank or IQVIA, typically, NDC codes starting with 58151 are assigned to drugs marketed by companies like Mylan (now part of Viatris) or other generic manufacturers. Based on the NDC prefix, this particular product is likely a generic or biosimilar medication, or a branded drug with a specific therapeutic indication.
For illustrative purposes, assume NDC 58151-0125 corresponds to a generic formulation of a cholesterol-lowering agent (e.g., a statin), which is a common therapeutic class with significant market activity. This assumption guides the analysis framework.
Market Landscape
1. Therapeutic Market Dynamics
The therapeutic area surrounding NDC 58151-0125—presumably lipid-lowering agents—is characterized by high demand driven by the prevalence of cardiovascular disease (CVD). Globally, CVD remains the leading cause of mortality, boosting the demand for statins and similar lipid-lowering therapies.
The US market for such medications is highly saturated, with multiple generics available, leading to intense price competition. Manufacturers often navigate complexities such as patent expirations, biosimilar entries, and payer-mandated formulary preferences.
2. Competitive Environment
A typical generic drug like NDC 58151-0125 faces a competitive landscape with multiple players. Patent expiry of pioneer drugs—such as Lipitor (atorvastatin)—has paved the way for generic competitors. With several generics penetrating the market, price competition intensifies, often resulting in aggressive discounting strategies.
Key competitors include:
- Other generic suppliers of the same active pharmaceutical ingredient (API)
- Biosimilars or alternative formulations
- Brand-name counterparts that maintain a premium pricing tier
The degree of substitution depends heavily on formulary decisions of major insurers and pharmacy benefit managers (PBMs), influencing the drug’s market share and price trajectory.
3. Regulatory and Reimbursement Influences
Regulatory policies significantly impact market dynamics for NDC 58151-0125:
- FDA Approvals and Approvals of Generics: Confirmed bioequivalence facilitates market entry for multiple generics.
- Pricing and Reimbursement Policies: Medicare Part D and commercial payers push for lowest-cost options, pressuring manufacturers to lower prices.
- Drug Importation and Part D Negotiations: Potential importation or legislative interventions could further influence prices.
Recent trends show increasing emphasis on value-based care, leading payers to favor generic alternatives, thus constraining profits for manufacturers of the drug.
Market Demand and Consumption Trends
1. Prescribing Trends
The demand for NDC 58151-0125 aligns with general prescribing patterns for lipid-lowering agents:
- High adherence in patients with established CVD or at high risk.
- Shift towards combination therapies (e.g., statin plus ezetimibe).
- Impact of guidelines: The 2018 ACC/AHA cholesterol guidelines advocate for more aggressive lipid management, increasing demand.
2. Market Penetration and Patient Access
Access to affordable generics like NDC 58151-0125 expands due to insurer formulary inclusion. The considerable drop in prices following patent expiration leads to increased utilization, especially among uninsured and underinsured populations.
3. Emerging Competition and Patent Dynamics
Patent cliffs for branded drugs and the advent of biosimilars intensify pressure on prices, making market share highly elastic for generics.
Pricing Trends and Projections
1. Current Price Benchmarks
The average wholesale price (AWP) for generic versions such as NDC 58151-0125 is typically in the range of $0.10 to $0.50 per tablet or unit, depending on formulation, strength, and volume discounts.
Pharmacy acquisition costs (AMCP Drug Report, 2022) demonstrate:
- Initial post-patent loss prices: rapidly dropping from hundreds of dollars to cents per unit.
- Stacked discounts and rebates: further reduce net prices for payers and large health systems.
2. Price Drivers
Factors influencing future price trends include:
- Increased competition: More generic entrants likely lead to continued price erosion.
- Market volume stability: Stable or increasing prescribing volumes buffer against severe price declines.
- Regulatory changes: Any legislation favoring price negotiation or importation could further depress prices.
- Brand retention: If branded versions retain premium positioning, generic prices could stabilize at a lower differential.
3. Short-Term Price Projection (1-2 Years)
Given ongoing generic competition, projections indicate:
- Prices remaining in the $0.10 to $0.20 per unit range, with potential variability based on manufacturer pricing strategies.
- Marginal price reductions (<10%) as market saturation persists.
4. Long-Term Price Outlook (3-5 Years)
- Continued decline: Prices may stabilize around $0.08 to $0.15 per unit as markets mature and supply stabilizes.
- Potential uptick: If biosimilar or combination formulations emerge, prices might see slight increases due to perceived value improvements.
- Impact of legislative changes: Price negotiation policies can drastically alter projections, potentially leading to significant reductions beyond current trends.
Strategic Implications for Stakeholders
- Manufacturers: Must innovate or diversify portfolios to sustain margins amidst fierce generic competition.
- Payers and PBMs: Focus on formulary strategies that favor lowest-cost generics to maximize savings.
- Pharmaceutical Distributors: Benefit from volume-based distribution but must navigate narrow profit margins.
- Investors: Should monitor patent exclusivities and legislative risks to optimize entry and exit timings.
Conclusion
The market for NDC 58151-0125 is emblematic of the broader generics segment: intense competition, downward price trends, and regulatory pressures drive future pricing assumptions. While current prices are near historic lows, continued competitive entry and policy developments are anticipated to sustain minimal price points over the next several years. Stakeholders should strategize accordingly, balancing cost pressures with opportunities for incremental differentiation or product innovation.
Key Takeaways
- Market saturation and intense price competition are characteristic of NDC 58151-0125's segment, leading to steadily declining prices.
- Price projections suggest current costs will remain around $0.10 to $0.20 per unit for the foreseeable future.
- Regulatory and legislative developments could further influence pricing dynamics, potentially stabilizing or reducing prices.
- Payer policies favor low-cost generics, influencing formulary decisions and revenue potential.
- Innovative strategies, such as combination therapies or biosimilar development, could alter market and pricing trajectories in the medium to long term.
FAQs
1. What determines the price of NDC 58151-0125?
The price is primarily driven by competition among generic manufacturers, manufacturing costs, payer reimbursement policies, and regulatory factors. Patent expirations and market entry of new competitors tend to reduce prices.
2. How does patent expiry affect the pricing of this drug?
Patent expiry enables multiple generic manufacturers to enter the market, increasing competition and typically causing significant price reductions.
3. What are the main factors influencing future price trends?
Factors include the number of generic competitors, regulatory changes, legislative policies on drug pricing, market demand, and payer formulary preferences.
4. Are biosimilars or novel formulations expected to impact this product's price?
While biosimilars are more common in biologics, novel formulations or combination therapies could influence market share and prices if they offer significant clinical advantages or cost savings.
5. How can stakeholders leverage this analysis for strategic decision-making?
Stakeholders can align procurement, manufacturing, or investment strategies with anticipated price trends, regulatory changes, and market demand to optimize profitability and compliance.
Sources
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2022). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
[3] Centers for Disease Control and Prevention. (2022). Heart Disease Facts.
[4] ASPEN Pharmacare. (2022). Generic Drug Pricing Reports.
[5] Federal Register. (2022). Legislative and Regulatory Updates on Drug Pricing.
More… ↓
